New Study Offers Hope for People with Chronic Hip Tendinopathy

Prospective multicenter research finds that a minimally invasive, ultrasound-guided procedure using the TenJet device significantly reduced pain and improved function at six months in patients with recalcitrant gluteal tendinopathy.

NORTH BILLERICA, Mass., Sept. 30, 2026 /PRNewswire-PRWeb/ -- Chronic pain on the outside of the hip can make it difficult to sleep on one side, climb stairs, or sit for long periods. For many patients with gluteal tendinopathy, also known as greater trochanteric pain syndrome, symptoms persist despite conservative care. New research published this month in Cureus reports on the use of an ultrasound-guided procedure with TenJet in patients with recalcitrant gluteal tendinopathy.(1)

The ongoing prospective multicenter study followed 46 patients with long-standing gluteal tendinopathy who had tried at least one conservative treatment before enrolling. Patients underwent a minimally invasive, ultrasound-guided procedure in an outpatient setting with the TenJet device. TenJet, developed by HydroCision, Inc. is designed for the targeted, selective removal of degenerative, pathologic tendon tissue while preserving adjacent healthy tissue.

A common problem with few good answers

The condition, known clinically as greater trochanteric pain syndrome, is one of the most frequent causes of hip pain seen in primary care, accounting for an estimated 10 to 20 percent of all hip pain visits.(2) It affects women far more often than men, particularly in middle age and later life.(2) For decades it was assumed to be bursitis, an inflammation problem. It is now understood to be primarily a tendon problem, known as gluteal tendinopathy: the gluteal tendons on the side of the hip gradually break down, with the tendon's collagen becoming disorganized and failing to heal on its own.(3)

That distinction matters because conservative treatments may not fully address the underlying tendon pathology. Research has found that roughly a third of patients still have pain a year after starting treatment, and nearly three in ten are still in pain five years later.(4)

For patients whose symptoms persist, the treatment path can be limited. Many have partial tendon damage and may not be candidates for open surgical repair, yet the pain and functional limitations can remain significant. The study's authors note that there is no clinical consensus on the next step for patients who remain symptomatic after conservative treatment.

What comes next

The published results are an interim six-month analysis from an ongoing study. Patients will continue to be followed for a full two years to evaluate longer-term results. The study did not include a comparison group receiving a different treatment, so it measures patient outcomes after procedure with TenJet rather than comparing the outcomes with alternative treatments.

The research is being conducted across multiple academic centers(5), with patients consenting to study participation before treatment and outcomes collected prospectively rather than retrospectively from patient records. This design provides stronger clinical evidence than smaller, single-center retrospective reports that have made up much of the published evidence in this field to date.

About Rothman Orthopaedics

Rothman Orthopaedics is a world-leader in the field of orthopedics, providing communities in Pennsylvania, New Jersey, and Florida with high-quality, compassionate, and affordable musculoskeletal care that is grounded in evidence-based medicine—the results of which will exceed expectations.

Rothman Orthopaedics providers treat patients at 32 office locations and have surgical privileges at over 70 facilities. With experts in ten orthopedic specialties, including spine, hip and knee, foot and ankle, shoulder and elbow, hand and wrist, sports medicine, physical medicine and rehabilitation, orthopedic oncology, trauma and fracture care, Rothman Orthopaedics is recognized for excellence in clinical treatment methods, research, education, and technology.

Consistently recognized as national and regional "Top Docs," Rothman Orthopaedics is proud to be the official team physicians for the Philadelphia Phillies as well as over 40 college and high school teams, including Drexel University and Villanova University. Center City District and the Philadelphia Marathon are among the more than 100 corporate and community organizations that Rothman partners with annually. For more information about Rothman Orthopaedics, please call (800) 321-9999 or visit www.RothmanOrtho.com.

About TenJet

TenJet is patented medical device from HydroCision, Inc. used to treat chronic tendon pain by applying HydroCision's FluidJet technology for targeted, selective removal of degenerative, pathologic tendon tissue while preserving adjacent healthy tissue. TenJet procedures are performed with real-time ultrasound image guidance in an outpatient setting. To learn more about TenJet, visit https://www.hydrocision.com/product/tenjet-tenotomy-device/tenjet-patient/

About HydroCision, Inc.

HydroCision, Inc., based in North Billerica, Massachusetts, focuses on the commercialization of its proprietary FluidJet technology including TenJet. HydroCision's portfolio includes technologies and devices that utilize pressurized saline for targeted tissue resection across a broad array of clinical applications. These minimally invasive solutions are designed to support precise tissue removal and improve surgical outcomes across a range of medical specialties.

References

1. Dakkak M, Furey G, Rosero E, et al. (September 03, 2026) Ultrasound-Guided Minimally Invasive Tenotomy Utilizing TenJet for Recalcitrant Gluteal Tendinopathy: A Six-Month Interim Analysis From a Prospective Multicenter Study. Cureus 18(9): e115717. doi:10.7759/cureus.115717
   
   
2. Mellor R, Bennell K, Grimaldi A, et al. Education plus exercise versus corticosteroid injection use versus a wait and see approach on global outcome and pain from gluteal tendinopathy: prospective, single blinded, randomised clinical trial. BMJ. 2018;361:k1662.
   
   
3. Khan KM, Cook JL, Kannus P, Maffulli N, Bonar SF. Time to abandon the "tendinitis" myth. BMJ. 2002 Mar 16;324(7338):626-627. doi: 10.1136/bmj.324.7338.626. PMID: 11895810. PMCID: PMC1122566.
   
   
4. Lievense A, Bierma-Zeinstra S, Schouten B, Bohnen A, Verhaar J, Koes B. Prognosis of trochanteric pain in primary care. Br J Gen Pract. 2005 Mar;55(512):199-204. PMID: 15808035. PMCID: PMC1463090.
   
   
5. Affiliations of the study authors include: Cleveland Clinic Florida, Cleveland Clinic Foundation, Rothman Orthopaedics, University of North Carolina School of Medicine, Stanford University, Atrium Health, Ochsner Health, and Penn Highlands Healthcare.

Media Contact

Debra Kurtz, Hydrocision Inc, 1 (978) 474-9300, [email protected], hydrocision.com

View original content:https://www.prweb.com/releases/new-study-offers-hope-for-people-with-chronic-hip-tendinopathy-302894086.html

SOURCE Rothman Orthopaedics